everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...6162636465666768697071...132133»
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Marcromolecular Architecture and Encapsulation of the Anticancer Drug Everolimus Controls the Self-Assembly of Amphiphilic Polypeptide-Containing Hybrids. (Pubmed Central) -  Sep 19, 2020   
    Encapsulation of the hydrophobic anticancer drug Everolimus resulted in the formation of intriguing non-spherical and non-symmetric pH-responsive nanostructures, such as "stomatocytes" and "multi-compartmentalized suprapolymersomes", while the pH-triggered release of the drug was also investigated. Owing to the similarities of the developed "stomatocytes" with red blood cells, in combination with their pH-responsiveness and superior stability over enzymatic degradation, they are expected to present advanced drug delivery properties and have the ability to bypass several extra- and intracellular barriers to reach and effectively treat cancer cells.
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Journal:  Long-Term Effects of the Replacement of Calcineurin Inhibitors With Everolimus and Mycophenolate in Patients With Calcineurin Inhibitor-Related Nephrotoxicity. (Pubmed Central) -  Sep 18, 2020   
    Owing to the similarities of the developed "stomatocytes" with red blood cells, in combination with their pH-responsiveness and superior stability over enzymatic degradation, they are expected to present advanced drug delivery properties and have the ability to bypass several extra- and intracellular barriers to reach and effectively treat cancer cells. A therapeutic switch from CNIs to everolimus and mycophenolate mofetil can improve renal function in patients with CNI nephrotoxicity, especially in those with a shorter time period from transplantation, without exposing them to a higher incidence of late acute rejection and cardiac allograft vasculopathy.
  • ||||||||||  everolimus / Generic mfg., paclitaxel / Generic mfg.
    Journal:  Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer. (Pubmed Central) -  Sep 18, 2020   
    Furthermore, the triple combination also synergistically increased the anti-tumor activity of paclitaxel, both in vitro and in vivo. Taken together, our results demonstrate that simultaneous inhibition of several signaling pathways results in better anti-tumor activity compared to inhibiting any of these signaling pathways alone.
  • ||||||||||  everolimus / Generic mfg.
    Enrollment closed, Trial completion date, Combination therapy, Stroma:  Mesenchymal Stromal Cell Therapy in Renal Recipients (clinicaltrials.gov) -  Sep 17, 2020   
    P2,  N=70, Active, not recruiting, 
    The transepithelial electrical resistance at the RKO-AS45-1 monolayer treated with everolimus started to decrease at 48 h. The changes in the gene expression and epithelial resistance may confirm the role of everolimus in EMT. Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Jan 2022
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Pathological Analysis Reveals Causes of Poor Patency After Endovascular Therapy for Below-the-knee Lesions (OnDemand) -  Sep 17, 2020 - Abstract #AHA2020AHA_2748;    
    After BTK endovascular therapy, cases treated by BA alone had poor patency due to insufficient luminal expansion, whereas those treated by BA and DES implantation had organized thrombus formation caused by slow and limited flow inside the DES due to intimal hyperplasia in the proximal segment. Smooth muscle cell proliferation inside the DES may be inhibited by the effect of the drug coated on the DES.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. (Pubmed Central) -  Sep 16, 2020   
    Expert opinion: Unlike many other therapies for treating TSC-associated seizures, everolimus addresses the underlying pathophysiology of TSC, and since it has also been shown to improve other TSC manifestations such as subependymal giant cell astrocytomas and renal angiomyolipomas, everolimus provides a potential multisystemic therapy for TSC. An important avenue for future research is exploring the possible use of everolimus as a preventative treatment for seizures as there is the potential to prevent negative developmental outcomes associated with TSC.
  • ||||||||||  tacrolimus / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  Feasibility of Immunosuppressant Drug Monitoring by a Microsampling Device. (Pubmed Central) -  Sep 16, 2020   
    An important avenue for future research is exploring the possible use of everolimus as a preventative treatment for seizures as there is the potential to prevent negative developmental outcomes associated with TSC. This feasibility study demonstrates that precision and bias of ≤15% can be achieved for microsampling-based ISP monitoring.
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  Mouse tumor susceptibility genes identify drug combinations for multiple myeloma. (Pubmed Central) -  Sep 16, 2020   
    The identification of MYC as a primary upstream regulator led to the identification of small molecule binders of the G-quadruplex structure that forms in the NHEIII region of the MYC promoter. These studies highlight the importance of identifying drug combinations which simultaneously upregulate tumor suppressors and downregulate oncogenes.
  • ||||||||||  avutometinib (VS-6766) / Verastem
    Trial completion date, Trial primary completion date, Combination therapy:  DDU RAF/MEK: Phase I Trial of VS-6766 Alone and in Combination With Everolimus (clinicaltrials.gov) -  Sep 14, 2020   
    P1,  N=94, Recruiting, 
    These studies highlight the importance of identifying drug combinations which simultaneously upregulate tumor suppressors and downregulate oncogenes. Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Dec 2021
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg., rapamycin topical (PTX-022) / Palvella Therapeutics, Ligand
    Journal:  Fas ligand and nitric oxide combination to control smooth muscle growth while sparing endothelium. (Pubmed Central) -  Sep 13, 2020   
    Selected doses of FasL and NO donor synergistically increased SMC apoptosis and inhibited SMC growth more potently than did everolimus or sirolimus, while having no significant effect on EC viability and proliferation...FasL and NO donor, released from the stent coating, killed SMCs close to the stent struts, even in the presence of flow rates mimicking those of native arteries. Thus, the FasL-NO donor-combination has a potential to prevent intimal hyperplasia and in-stent restenosis, without harming endothelial restoration, and hence may be a superior drug delivery strategy for DES.
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas. (Pubmed Central) -  Sep 10, 2020   
    Everolimus, pazopanib, axitinib and nivolmab might also be viable options...Evidence is still lacking regarding the treatment for other rare non-clear cell renal cell carcinomas. Appropriate sequential therapies using antivascular endothelial growth factor therapies, mammalian target of rapamicin inhibitors and immuno-oncology drugs should be established for each non-clear cell renal cell carcinoma.
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  Glucagonoma: From skin lesions to the neuroendocrine component (Review). (Pubmed Central) -  Sep 10, 2020   
    If surgery is not curative, debulking techniques may improve the clinical aspects and even the outcome in association with other procedures such as embolization of hepatic metastasis; ablation of radiofrequency type; medical therapy including chemotherapy, targeted therapy with mTOR inhibitors such as everolimus, PRRT (peptide receptor radiotherapy), and somatostatin analogues (including combinations of medical treatments). Increased awareness of the condition involves multidisciplinary practitioners.
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). (Pubmed Central) -  Sep 9, 2020   
    These mutations cause hyperactivation of the mechanistic target of rapamycin (mTOR)...Patients with TSC should undergo periodic screening with CT or preferably MRI scans of the brain from childhood to approximately age 25 to identify SEGAs which require treatment. In addition to avoiding potential morbidity associated with surgical resection, mTOR inhibitors have the potential to improve the clinical status of tuberous sclerosis patients generally.
  • ||||||||||  tacrolimus / Generic mfg., everolimus / Generic mfg.
    Clinical, Journal:  Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients. (Pubmed Central) -  Sep 1, 2020   
    mTORC1 inhibitors-notably temsirolimus with an improved water solubility-but not dual mTOR inhibitors protect against inflammation-induced apoptosis, senescence, and matrix catabolism in human disc cells, which depends on Akt and autophagy induction. This study showed that EVR is associated with a beneficial effect on glomerular filtration rate in both the short and long term in LT recipients.
  • ||||||||||  tacrolimus / Generic mfg., everolimus / Generic mfg.
    Clinical, Journal:  Descriptive Analysis of Everolimus Conversion in Liver Transplant Recipients With Malignant Neoplastic Disease. (Pubmed Central) -  Sep 1, 2020   
    This study showed that EVR is associated with a beneficial effect on glomerular filtration rate in both the short and long term in LT recipients. Although the beneficial long-term role of EVR in liver transplant recipients with tumor disease is not demonstrated, it is used by most transplant units, both in de novo neoplasms and those receiving transplants because of hepatocellular carcinoma.
  • ||||||||||  everolimus / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Review, Journal:  Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. (Pubmed Central) -  Aug 30, 2020   
    In the pivotal Phase 3 METEOR trial, cabozantinib significantly improved overall survival, progression-free survival and the objective response rate compared with everolimus in patients with advanced RCC who had received previous treatment with a VEGFR TKI...Dose reduction of cabozantinib to manage AEs is predicted to have minimal impact on efficacy as AEs are more likely to occur in patients with low clearance and higher exposure to cabozantinib. These analyses further support a dose modification strategy to optimize cabozantinib exposure for individual patients.
  • ||||||||||  tacrolimus / Generic mfg., everolimus / Generic mfg.
    Effects of everolimus on renal function in liver transplant patients () -  Aug 30, 2020 - Abstract #JSN2020JSN_324;    
    0.41±0.09→2.39±0.98 g/g・Cr, urinary NAG14.8±0.03→13.7±0.06 IU/g・Cr, urinary β2MG 6.4±4.0→4.4±1.9 mg/g・Cr, eGFR36.7 ±1.95→41.4±2.79ml/min, TG188.7±24.9→204.2±31.6mg/dl, LDL-C100.5±12.6→125.4±12.8mg/dl, HgA1c5.85±0.34→5.93±0.20% It was found that in many cases, EVR introduction improved the eGFR in the short term, but urinary protein increased in the liver transplant patients. Needs consideration.
  • ||||||||||  Triglide (fenofibrate) / Vectura, Shionogi, tacrolimus / Generic mfg., everolimus / Generic mfg.
    [VIRTUAL] Outcomes of everolimus after heart transplantation (E-Poster Hall) -  Aug 29, 2020 - Abstract #TTS2020TTS_1493;    
    Frequent indications for EVL were CKD and CAV. Concentration-controlled EVL (C0 target 3.0-6.5 ng/ml) in combination with reduced TAC achieved good efficacy and safety, higher C0 target was associated with frequent infectious complications.
  • ||||||||||  tacrolimus / Generic mfg., everolimus / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] ABO-incompatible pediatric liver transplantation: Experience of 122 procedures at a single center (E-Poster Hall) -  Aug 29, 2020 - Abstract #TTS2020TTS_1392;    
    In 26 children with elevated anti-ABO titers (1:16-1:128) and without urgent indications for transplantation the desensitization included the only transfusion of AB(IV) fresh frozen plasma. In 37 patients with high anti-ABO titers (up to 1:256) plasmapheresis was carried out preoperatively; 19 also received rituximab infusion.